BJH - volume 9, issue Abstract Book BSTH, february 2018

K.R. Six , W. Delabie , R. Devloo , L. Johnson , D.C. Marks , L. Dumont , K.M. Devreese , H.B. Feys PhD, Prof V. Compernolle PhD

Read more

Massive clotting in red cell concentrates during transfusion is caused by backflow of patient blood

BJH - volume 8, issue 5, september 2017

B. Van Aelst PhD, J. Coene MD, H.B. Feys PhD, M.P. Emonds MD, PhD, K. Van Poucke MD, J. Moerman MD, E. Verhoye MPharm , Prof V. Compernolle PhD


We report three cases of massive ex vivo coagulation in a leukocyte depleted red cell concentrate during transfusion. Molecular blood typing indicated that patient blood was present in the filter housing of the infusion set and/or in the blood bag itself. Together with the history of events, this suggested that the observed clotting was caused by backflow of patient blood. Therefore, we recommend maintaining the blood bag above heart level during the entire transfusion procedure, until the infusion set is removed.

(BELG J HEMATOL 2017;8(5):195–7)

Read more

Pathogen inactivation of blood components, impact on plasma and platelet function

BJH - volume 7, issue 6, december 2016

B. Van Aelst PhD, H.B. Feys PhD, R. Devloo , Prof P. Vandekerckhove PhD, Prof V. Compernolle PhD


Pathogen inactivation technologies are photochemical treatments developed to decrease transfusion transmitted infections. However, the impact of pathogen inactivation technologies on the blood components themselves is not entirely clear. Therefore, we investigated the quality of blood components following pathogen inactivation. First, the impact of three different pathogen inactivation technologies on plasma was compared. The different methods all negatively affected ADAMTS13 activity and antigen level, but to different degrees. The pathogen inactivation technology using riboflavin as a photosensitizer had the largest effect. This effect was caused by reactive oxygen because removal of dissolved molecular oxygen prevented protein damage to occur. Next, we investigated the influence of three different pathogen inactivation technologies on platelet concentrates. For this, platelet function was assessed in microfluidic flow chamber experiments. These indicated a decreased platelet function compared to untreated controls for all pathogen inactivation technologies. Additional experiments showed that the underlying mechanisms of platelet damage were different for every pathogen inactivation technology, but all three resulted in similar thrombus formation deficiencies in flow chambers. We focused on one particular pathogen inactivation technology which combines the photosensitizer amotosalen (a psoralen) and UVA light (PUVA). The data showed a specific inhibition of the phosphatidylinositol 3-kinase signal transduction pathway caused by covalent binding of amotosalen to phospholipids during photoactivation. As the combination of a psoralen with UVA light is clinically used off-label for graft-versus-host disease treatment, phosphatidylinositol 3-kinase signal transduction in T lymphocytes of patient samples was studied and also here inhibition of phosphatidylinositol 3-kinase signal transduction was found. To conclude, research that initiated from the observation that platelet and plasma function is decreased following pathogen inactivation technologies has revealed an overall effect of PUVA on cellular phosphatidylinositol 3-kinase signal transduction by covalent modification of phospholipids.

(BELG J HEMATOL 2016;7(6):240–3)

Read more

Apheresis platelet concentrates with persistent particles

BJH - 2014, issue Abstract Book BSTH, november 2014

B. Van Aelst PhD, H.B. Feys PhD, R. Devloo , Prof P. Vandekerckhove PhD, J. Coene MD, Prof V. Compernolle PhD

Read more

Three photochemical pathogen inactivation methods impair platelet function with different underlying biochemical mechanisms

BJH - 2014, issue Abstract Book BSTH, november 2014

B. Van Aelst PhD, R. Devloo , Prof P. Vandekerckhove PhD, Prof V. Compernolle PhD, H.B. Feys PhD

Read more